Drug Type Trispecific killer cell engager (TriKE) |
Synonyms- |
Target |
Action modulators |
Mechanism CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators), Interleukin-15 receptors modulators(Interleukin-15 receptors modulators), MSLN modulators(Mesothelin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | United States | 09 Mar 2022 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 09 Mar 2022 |